Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics
Mathematical modeling of the time-course of drug exposure (pharmacokinetics, PK) and associated pharmacological effects (pharmacodynamics, PD) has evolved from a simple descriptive endeavor to an essential component of model-based drug development. The role of PK/PD modeling can be more critical for antibody-based therapeutics owing to their complex pharmacological properties. Nonlinear behavior can manifest in most of the physiological processes controlling antibody PK, and mechanisms of drug response are inherently nonlinear and often involve turnover of endogenous ligands and biomarkers. In this chapter, model concepts and features that are common to antibody-based therapeutics are highlighted, along with applications of such models for understanding inter-species differences in concentration-effect relationships, selecting first-in-human doses, designing regimens for clinical studies, and linking PK/PD relationships to clinical outcomes. To improve prospective model predictions of drug efficacy and safety, new approaches will be needed to link antibody disposition with robust systems pharmacology models of drug and disease mechanisms.
KeywordsPBPK Model Allometric Scaling Pharmacodynamic Model Dose Selection Indirect Response Model
Financial support from NIH Grant GM57980, the Center for Protein Therapeutics, University at Buffalo, SUNY (UB), and the UB-Pfizer Strategic Alliance is gratefully appreciated. I thank Dr. Sihem Ait-Oudhia at UB for her assistance in constructing figures.
- Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA et al (2010) The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333(1):2–13PubMedCrossRefGoogle Scholar
- Ferraiolo BL, Mohler MA, Gloff CA (eds) (1992). Protein pharmacokinetics and metabolism, vol 1. Plenum Press, New YorkGoogle Scholar
- Gabrielsson J, Weiner D (2000) Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 3rd edn. Swedish Pharm Press, StockholmGoogle Scholar
- Jusko WJ (2005) Guidelines for collection and analysis of pharmacokinetic data. In: Leslie M, Schentag JJ, Evans WE, Burton ME (eds) Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring, 3rd edn. Applied Therapeutics Inc. VancouverGoogle Scholar
- Kereiakes DJ, Broderick TM, Roth EM, Whang D, Mueller M, Lacock P et al (2000) High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. J Thromb Thrombolysis 9(2):149–155PubMedCrossRefGoogle Scholar